Related Experiment Videos
Over 20 years' experience of beta-blockade in heart failure
1Cardiology and Clinical Pharmacology, Université Henri Poincaré, Nancy, France.
Abstract:
The use of beta-blocker therapy in heart failure was contraindicated for many years because it was considered to block necessary sympathetic compensatory responses to reduced cardiac function. However, early studies provided promising results in terms of improved symptoms and work capacity and reduced heart size. Small-scale studies have been completed over the past 20 years but until large-scale, long-term, randomized trials were conducted, the potential of beta-blockers in heart failure was not confirmed. The results of randomized trials published to date have included over 3,000 patients and the results show improvements in left ventricular function and heart rate. Significant improvements in New York Heart Association classification were also shown. Although no conclusive effect on mortality was shown, the first Cardiac Insufficiency Bisoprolol Study (CIBIS) indicated a trend toward improved survival during long-term treatment with bisoprolol. Ongoing studies have been specifically designed to investigate the effects of beta-blockers on survival. One of these trials, CIBIS II, which was terminated early in 1998 because of a positive effect on survival, is expected to report in late summer 1998. Such trials will also examine the different mechanisms of action of beta-blockers in heart failure and the influence of causes on the effects of beta-blockade.
Insights
Beta-blocker therapy, once contraindicated for heart failure, now shows promise. Large trials confirm improved heart function and symptoms, with ongoing studies investigating survival benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blocker therapy was historically contraindicated in heart failure due to concerns about inhibiting necessary sympathetic responses.
- Early small-scale studies suggested potential benefits, including improved symptoms and cardiac function.
Purpose of the Study:
- To evaluate the efficacy and safety of beta-blocker therapy in patients with heart failure.
- To confirm the findings of earlier studies through large-scale, long-term, randomized trials.
Main Methods:
- Analysis of data from large-scale, long-term, randomized trials involving over 3,000 patients.
- Assessment of left ventricular function, heart rate, and New York Heart Association (NYHA) classification.
Main Results:
- Beta-blocker therapy demonstrated significant improvements in left ventricular function and heart rate.
- Patients treated with beta-blockers showed significant improvements in NYHA classification.
- While not conclusively affecting mortality, some studies indicated a trend toward improved survival.
Conclusions:
- Large-scale randomized trials have confirmed the beneficial effects of beta-blockers in heart failure management.
- Further research, including ongoing trials like CIBIS II, is crucial to fully elucidate the impact of beta-blockers on survival and their mechanisms of action in heart failure.